US FDA recommends annualized bleeding rate as the primary efficacy endpoint for traditional approval of hemophilia gene therapies. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
